A combined drug and drug composition for treating solid tumors

By combining ribosomal inhibitors and JNK-USP36-Snail pathway inhibitors, targeting the inhibition of JNK-USP36-Snail signaling pathway, solving the problem of solid tumors not responding to ribosomal inhibitors, significantly inhibiting tumor growth, and providing new treatment strategies.

CN116870167BActive Publication Date: 2024-11-08SICHUAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311074572.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-08-24
Publication Date
2024-11-08
Estimated Expiration
2043-08-24

AI Technical Summary

Technical Problem

Solid tumors do not respond to ribosomal inhibitors such as high-serum ceramide, resulting in poor treatment effects, and the relationship between USP36-Snail1-related pathways and anti-tumor has not been fully explored.

Method used

The use of ribosome inhibitors and JNK-USP36-Snail pathway inhibitors enhances the sensitivity of tumor cells to ribosome inhibitors by targeting the inhibition of the JNK-USP36-Snail signaling pathway.

Benefits of technology

Significantly inhibiting tumor cell survival and tumor growth in vitro provides a new tumor treatment strategy and increases treatment options for cancer patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116870167B_ABST
    Figure CN116870167B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of medical technology, and specifically relates to a combination drug and a pharmaceutical composition for treating solid tumors. The present invention has found that activating the JNK-USP36-Snail1 signaling pathway is the key for solid tumors to resist ribosomal inhibitors including homoharringtonine. Targeted inhibition of the JNK-USP36-Snail signaling pathway will enhance the sensitivity of solid tumor cells to ribosomal inhibitors. Based on this, the present invention proposes to treat solid tumors by combining ribosomal inhibitors and JNK-USP36-Snail pathway inhibitors, which is a new strategy that can provide more options for the clinical treatment of cancer patients.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and in particular relates to a combined drug and a drug composition for treating solid tumors. Background Art

[0002] Ribosomes are the protein synthesis center in cells. Tumor growth requires the improvement of ribosome function to meet the protein synthesis required for its rapid growth. Therefore, inhibiting ribosome function is considered an important strategy for tumor treatment. Homoharringtonine (HHT) is a plant alkaloid isolated from harringtonine and is a highly effective anti-tumor drug independently developed in my country. HHT can bind to the ribosomal peptidyl transferase center to block protein synthesis. HHT is currently the only ribosome inhibitor used in clinical cancer treatment and is widely used in the treatment of acute non-lymphocytic leukemia. However, clinical studies have shown that solid tumors including head and neck cancer, breast cancer, colorectal cancer, and renal cancer do not respond to HHT treatment, and the reason is still unclear. Therefore, exploring the molecular mechanism of solid tumor cells resisting HHT is of great significance for expanding the application of HHT in tumor treatment.

[0003] Snail1 is an important transcription factor mainly located in the nucleoplasm of cells. It plays an important role in epithelial-mesenchymal transition (EMT), tumor metastasis and survival, metabolic reprogramming and tumor stem cell characteristics. However, there is no report on whether Snail1 can be localized in the nucleolus and participate in the regulation of ribosome generation. Snail1 protein is mainly degraded through the ubiquitin-dependent proteasome pathway, so ubiquitination and deubiquitination regulation are key factors affecting the stability of Snail1 protein. USP36 is a deubiquitinating enzyme specifically located in the nucleolus. It promotes ribosomal rRNA transcription and processing by stabilizing proteins such as B23, fibronectin (FBL) and c-Myc, thereby promoting ribosome generation.

[0004] At present, there are no other reports on the relationship between the USP36-Snail1 pathway and anti-tumor effects. Summary of the invention

[0005] In view of the problems of the prior art, the present invention provides a combined drug and a pharmaceutical composition for treating solid tumors, aiming at treating solid tumors by combining a ribosome inhibitor including homoharringtonine and a JNK-USP36-Snail pathway inhibitor.

[0006] Use of JNK-USP36-Snail pathway inhibitors in the preparation of drugs for eliminating solid tumor resistance to ribosome inhibitors.

[0007] The present invention also provides use of a ribosome inhibitor combined with a JNK-USP36-Snail pathway inhibitor in preparing a drug for treating solid tumors.

[0008] Preferably, the ribosome inhibitor is selected from at least one of homoharringtonine, anisomycin, puromycin, G418 or blasticidin.

[0009] Preferably, the JNK-USP36-Snail pathway inhibitor is selected from at least one of a JNK inhibitor, a USP36 inhibitor or a Snail1 inhibitor.

[0010] Preferably, the JNK inhibitor is selected from at least one of SP600125, JNK-IN-8, JNK-930 or Bentamapimod; the USP36 inhibitor is selected from specific siRNA for USP36; and the Snail1 inhibitor is selected from specific siRNA for Snail1.

[0011] Preferably, the solid tumor is lung cancer, head and neck cancer, breast cancer, colorectal cancer or kidney cancer.

[0012] The present invention also provides a combined drug for treating solid tumors, wherein the combined drug is a ribosome inhibitor and a JNK-USP36-Snail pathway inhibitor administered separately or simultaneously.

[0013] Preferably, the ribosome inhibitor is selected from at least one of homoharringtonine, anisomycin, puromycin, G418 or blasticidin.

[0014] Preferably, the JNK-USP36-Snail pathway inhibitor is selected from at least one of a JNK inhibitor, a USP36 inhibitor or a Snail1 inhibitor.

[0015] Preferably, the JNK inhibitor is selected from at least one of SP600125, JNK-IN-8, JNK-930 or Bentamapimod; the USP36 inhibitor is selected from specific siRNA for USP36; and the Snail1 inhibitor is selected from specific siRNA for Snail1.

[0016] Preferably, the combination drug is used to treat lung cancer, head and neck cancer, breast cancer, colorectal cancer or kidney cancer.

[0017] The present invention also provides a pharmaceutical composition, which is prepared by taking a ribosome inhibitor and a JNK-USP36-Snail pathway inhibitor as active ingredients and adding pharmaceutically acceptable excipients or auxiliary ingredients.

[0018] Preferably, the ribosome inhibitor is selected from at least one of homoharringtonine, anisomycin, puromycin, G418 or blasticidin.

[0019] Preferably, the JNK-USP36-Snail pathway inhibitor is selected from at least one of a JNK inhibitor, a USP36 inhibitor or a Snail1 inhibitor.

[0020] Preferably, the JNK inhibitor is selected from at least one of SP600125, JNK-IN-8, JNK-930 or Bentamapimod; the USP36 inhibitor is selected from specific siRNA for USP36; and the Snail1 inhibitor is selected from specific siRNA for Snail1.

[0021] Preferably, the ribosome inhibitor and the JNK-USP36-Snail pathway inhibitor are used in a weight ratio of 0.5:7.5-3:25.

[0022] The present invention has found through research that activating the JNK-USP36-Snail1 signaling pathway is the key to solid tumors resisting ribosomal inhibitors including homoharringtonine. Further studies using cell and animal models have found that: 1) the combination of JNK inhibitor SP600125 and ribosomal inhibitors can significantly inhibit tumor cell survival in vitro and solid tumor growth in vivo; 2) silencing USP36 or Snail1 using RNAi interference technology can significantly promote ribosomal inhibitor-mediated tumor cell death in vitro and tumor growth inhibition in vivo. The above experimental results show that targeted inhibition of the JNK-USP36-Snail signaling pathway will enhance the sensitivity of solid tumor cells to ribosomal inhibitors; therefore, the present invention proposes to treat solid tumors by combining ribosomal inhibitors and JNK-USP36-Snail pathway inhibitors, which is a new strategy that can provide more options for the clinical treatment of cancer patients.

[0023] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.

[0024] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 HHT promotes the nucleolar aggregation of Snail1 protein. (A) The indicated cells were treated with 20 ng / mL HHT for 24 hours, and then the subcellular localization of Snail1 protein was detected by immunofluorescence staining. B23 is a nucleolar marker and DAPI is a nuclear dye. The scale bar is 25 μm. (B) The co-localization of Snail1 protein and B23 protein in (A) was calculated using Pearson's correlation coefficient. 40 cells from three independent experiments were used for this calculation. (C) HCC1806 cells were treated with 20 ng / mL HHT for 24 hours, and then the cell fractions (CP, cytoplasm; NP, nucleoplasm; No, nucleolus) were separated and the expression of Snail1 protein in each fraction was detected by immunoblotting. Tubulin is a marker for the cytoplasm and SP1 is a marker for the nucleoplasm.

[0026] Figure 2 HHT promotes the nucleolar aggregation of Snail1 protein by increasing the expression of USP36. (A) The indicated cells were treated with 20 ng / mL HHT for 24 hours, and then treated with 50 μg / mL protein synthesis inhibitor cycloheximide (CHX) for the indicated time, and then the expression of Snail1 protein was detected by immunoblotting. Snail1 protein was quantified, and then the half-life of Snail1 protein was plotted. (B) HCC1806 cells were treated with 20 ng / mL HHT, 20 nM mTOR inhibitor rapamycin (Rap), 200 ng / mL ribosome inhibitor puromycin (Puro) and 2 μg / mL ribosome inhibitor blasticidin (Blasti) for 24 hours, and then the expression of USP36 and Snail1 proteins was detected by immunoblotting. (C) Wild-type USP36 (USP36-WT) or USP36 deubiquitinase inactive mutant USP36-C131A were stably expressed in HCC1806 and SUM159 cells, and then the expression of Snail1 protein was detected by immunoblotting. (D) USP36-WT or USP36-C131A was complemented in HCC1806 cells with USP36 knockdown (shUSP36), and then the expression of Snail1 protein was detected by immunoblotting. (E) USP36-WT or USP36-C131A was stably expressed in HCC1806 cells, and then the subcellular localization of Snail1 protein was detected by immunofluorescence staining. (F) HCC1806 cells with or without USP36 knockdown (shUSP36) or not knockdown (shGFP) were treated with 20 ng / mL HHT for 24 hours, and then the subcellular localization of Snail1 protein was detected by immunofluorescence staining. Scale bar is 25 μm.

[0027] Figure 3 USP36 is a deubiquitinase for nucleolar Snail1. (A) Immunoprecipitation assay to detect the formation of endogenous USP36 and Snail1 protein complex in the nucleolus. (B) Wild-type USP36 (USP36-WT) or the deubiquitinase inactive mutant USP36-C131A was stably expressed in HEK-293 cells, and then the cells were treated with 50 μg / mL protein synthesis inhibitor cycloheximide (CHX) for the indicated time, and then the expression of Snail1 protein was detected by immunoblotting, and the Snail1 protein was quantitatively analyzed, and then the half-life of Snail1 protein was plotted. (C) USP36 was knocked down in HCC1806 cells (shUSP36), and then the cells were treated with 50 μg / mL protein synthesis inhibitor cycloheximide (CHX) for the indicated time, and then the expression of Snail1 protein was detected by immunoblotting, and the Snail1 protein was quantitatively analyzed, and then the half-life of Snail1 protein was plotted. (D) Immunoprecipitation assay to detect the effect of USP36-WT or USP36-C131A on Snail1 protein ubiquitination. (E) Immunoprecipitation assay to detect the effect of knockdown of USP36 (shUSP36) on Snail1 protein ubiquitination. (F) Immunoprecipitation assay to detect the effect of USP36 on the ubiquitination of the indicated Snail1 proteins. (GH) Wild-type Snail1 (Snail1-WT) or Snail1-K146R / K206R mutant (Snail1-2KR) was stably expressed in HEK-293 cells, and the cells were treated with 50 μg / mL protein synthesis inhibitor cycloheximide (CHX) for the indicated time, and then the expression of Snail1 protein was detected by immunoblotting (G); Snail1 protein was quantified, and the half-life profile of Snail1 protein was plotted (H).

[0028] Figure 4 Lysine 157 (K157) on Snail1 protein is a key site for the formation of Snail1-USP36 protein complex and the nucleolar localization of Snail1. (A) ZDOCK predicted the key amino acid residues for the binding of Snail1 to USP36. (B) Immunoprecipitation was used to detect the binding of wild-type Snail1 (Snail1-WT) or Snail1-K157R to USP36 in the nucleolus. (CD) Cell component separation experiments were used to detect the effects of USP36 or HHT on the expression of Snail1 protein in the nucleolus (CP, cytoplasm; NP, nucleoplasm; No, nucleolus). (EF) Immunofluorescence staining was used to detect the effects of USP36 or HHT on the subcellular localization of Snail1 protein. Scale bar is 25 μm.

[0029] Figure 5HHT up-regulates USP36 expression by activating JNK. (A) HCC1806 cells were treated with 20 ng / mL HHT for 24 h, and then the mRNA expression of USP36 was detected by fluorescence quantitative PCR. (BC) HCC1806 cells were treated with 20 ng / mL HHT alone or in combination with 20 μM JNK inhibitor SP600125 for 24 h, and then the protein and mRNA expression of USP36 were detected by immunoblotting or fluorescence quantitative PCR. (D) HCC1806 cells were treated with 20 ng / mL HHT alone or in combination with 20 μM SP600125 for 24 h, and then the cell components (CP, cytoplasm; NP, nucleoplasm; No, nucleolus) were separated and the expression of Snail1 protein in each component was detected by immunoblotting. Tubulin is a marker for the cytoplasm of cells, and SP1 is a marker for the nucleoplasm.

[0030] Figure 6 Gene silencing of Snail1 or USP36 significantly promoted HHT-mediated tumor cell death in vitro and tumor growth inhibition in vivo. (AB) Snail1 knockdown HCC1806 cells were complemented with wild-type Snail1 (Snial1-WT) or Snail1 mutant Snail1-K157R that lost nucleolar localization, and HCC1806 cells were treated with 20 ng / mL HHT for 24 hours, and then (1) the expression of the indicated proteins was detected by immunoblotting (A); (2) cell apoptosis was detected by flow cytometry (B). (C) 5×10 5 The indicated HCC1806 cells were inoculated subcutaneously in the right neck of female BALB / c nude mice (n=5 / group); on the 3rd day after inoculation, HHT (1 mg / kg, daily) was injected intraperitoneally; on the 14th day, the mice were killed and the tumors were removed and photographed (C) and the weight of each tumor was measured (D). (EF) In HCC1806 cells with USP36 knockdown, Snail1-WT or Snail1-K157R was complemented, and the cells were treated with 20 ng / mL HHT for 24 hours, and then (1) the expression of the indicated proteins was detected by immunoblotting; (2) cell apoptosis was detected by flow cytometry.

[0031] Figure 7 The combination of JNK inhibitor SP600125 and HHT significantly inhibited tumor cell survival in vitro and tumor growth in vivo. (AB) The indicated cells were treated with 20 ng / mL HHT alone or in combination with 20 μM JNK inhibitor SP600125 for 24 hours, and then (1) the expression of the indicated proteins was detected by immunoblotting (A); (2) cell apoptosis was detected by flow cytometry (B). (CD) 5×10 5HCC1806 cells were inoculated subcutaneously in the right neck of female BALB / c nude mice (n=5 / group); on the 3rd day after inoculation, HHT (1 mg / kg) and SP600125 (15 mg / kg) were injected intraperitoneally daily alone or in combination; on the 17th day, the mice were killed, the tumors were removed and the weight of each tumor was measured (C); the expression of the proteins shown in each tumor tissue was detected by immunoblotting.

[0032] Figure 8 The combination of JNK inhibitor SP600125 and ribosome inhibitor anisomycin or blasticidin significantly inhibited tumor cell survival in vitro. (A) HCC1806 cells were treated with 50ng / mL anisomycin (Aniso), 200ng / mL puromycin (Puro), 1μg / mL G418, or 2μg / mL blasticidin (Blasti) for 24 hours, and then the subcellular localization of Snail1 protein was detected by immunofluorescence staining. B23 is a nucleolar marker and DAPI is a nuclear dye. The scale bar is 25μm. (B) The co-localization of Snail1 protein and B23 protein in (A) was calculated using Pearson's correlation coefficient. 40 cells from three independent experiments were used for this calculation. (C) The indicated HCC1806 cells were treated with ribosomal inhibitor HHT (20 ng / mL), anisomycin (50 ng / mL), puromycin (200 ng / mL), G418 (1 μg / mL), or blasticidin (2 μg / mL) for 24 hours, and then the nuclear localization of Snail1 protein was detected by immunofluorescence staining. About 200 cells in each group were randomly selected, and the percentage of nucleolar Snail1-positive cells was counted. (D-E) The indicated cells were treated with 20 ng / mL HHT, 50 ng / mL anisomycin (Aniso), 2 μg / mL blasticidin (Blasti) alone or in combination with 20 μM JNK inhibitor SP600125 for 24 hours, and then (1) the expression of the indicated proteins was detected by immunoblotting (D); (2) cell apoptosis was detected by flow cytometry (E). DETAILED DESCRIPTION

[0033] In the following examples and experimental examples, reagents and raw materials not specifically described are all commercially available products.

[0034] Example 1 Combination of Homoharringtonine and SP600125 for the Treatment of Cancer

[0035] This embodiment provides a combined drug of homoharringtonine and SP600125, which can be used simultaneously or separately. The usage ratio of homoharringtonine to SP600125 is a mass ratio of 1:15.

[0036] As a preferred embodiment, the combined drug is a 1 mg / kg aqueous solution of homoharringtonine and a 15 mg / kg aqueous solution of SP600125, which are used independently.

[0037] In other embodiments, the homoharringtonine in this embodiment can be replaced by other ribosomal inhibitors, such as anisomycin, puromycin, G418 or blasticidin.

[0038] The technical solution of the present invention is further illustrated by experiments below.

[0039] Experimental Example 1 Molecular mechanism of solid tumor cells resisting HHT

[0040] 1. Experimental Methods

[0041] 1. Cell culture

[0042] A549 (human non-small cell lung cancer), Hs 578T (human breast cancer), HCC1806 (human breast squamous cell carcinoma) and SUM159 (human breast cancer) cells were cultured in DMEM medium (Gibco, Rockville, MD, USA) supplemented with 10% fetal bovine serum (FBS, HyClone, Logan, UT, USA), 100 units / mL penicillin (Gibco, Rockville, MD, USA) and 100 μg / mL streptomycin (Gibco, Rockville, MD, USA). The cells were grown in a humidified incubator at 37°C and 5% CO2.

[0043] 2. Cell apoptosis and cell viability assay

[0044] The cells were cultured in 6-well plates. When the cell confluence rate was about 70%, the cells were treated with 20 ng / mL alone or in combination with 20 μM JNK inhibitor SP600125 (S1460, Houston, USA) for 24 hours. The cells were then incubated with Annexin V-FITC and PI (Beyotime, C1052, China), and cell apoptosis was analyzed by flow cytometry (FACScan, BD Biosciences, USA). For cell viability, MTS detection was performed using the CellTiter 96 kit (Promega, USA).

[0045] 3. Cellular component separation and in vivo Snail1 ubiquitination assay

[0046] Separation of cellular components of cytoplasm, nucleoplasm and nucleolus: Collect cells, wash twice with cold PBS, resuspend in 1 mL buffer A (10 mM Tris-HCl PH 7.8; 10 mM KCl; 1.5 mM MgCl2; 0.5 mM DTT) and place on ice for 10 minutes; then centrifuge at 228g for 5 minutes at 4°C, and the supernatant is the cytoplasmic fraction. Wash the cell pellet with buffer A, then with 1 mL buffer S1 (0.25 M sucrose; 10 mM MgCl2), layer on 1 mL buffer S2 (0.35 M sucrose, 0.5 mM MgCl2), and centrifuge at 1430g for 10 minutes at 4°C. The clean cell pellet was resuspended in 0.5 mL of buffer S2; sonicated at 20% full power for 12 × 10 seconds in an ice bath (resting for 10 seconds between each sonication) to prevent overheating of the sample, and then 0.5 mL of buffer S3 (0.88 M sucrose; 0.5 mM MgCl2) was added. Centrifuged at 3,000 g for 20 minutes at 4°C. The supernatant (nucleoplasmic fraction) and the pellet (nucleolar fraction) were collected. The nucleoli were resuspended in 0.5 mL of buffer S1 and 0.5 mL of 0.35 M buffer S2; centrifuged at 2500 rpm (1430 g) for 10 minutes at 4°C. For Western blot analysis, the insoluble fraction containing the nucleoli was lysed in 1× SDS sample buffer (#7722, CST) and sonicated if necessary. In co-immunoprecipitation experiments, nucleoli were lysed in high salt RIPA buffer (50 mM Tris pH 7.5, 500 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate and proteasome inhibitors).

[0047] For Snail1 protein ubiquitination experiments, the collected cells were lysed in pre-boiled denaturing cell lysis buffer (50mM pH7.4 Tris-HCl, 70mM β-ME, freshly added β-ME). The cell lysate was boiled for 10 minutes and 4 volumes of dilution buffer (20mM pH 7.4 Tris-HCl, 300mM NaCl, 1mM EDTA, 1mM EGTA, 1% Triton X-100, 2.5mM sodium pyrophosphate, 1mM β-glycerophosphate, 1mM Na3VO4, 1μg / mL pancreatic peptide) were added. The cell lysate was centrifuged at 12000g for 30 minutes, and then immunoprecipitated and analyzed by western blot.

[0048] 4. Western blot, co-immunoprecipitation and immunofluorescence staining analysis

[0049] For western blot analysis, cells were collected, washed twice with cold PBS, and then lysed in 1x SDS sample buffer (#7722, Cell Signaling Technology, USA). Equal amounts of protein were loaded into SDS-PAGE gels and separated by electrophoresis, and then the proteins were transferred to PVDF membranes (Millipore, Darmstadt, Germany). The membranes were blocked in 4% skim milk and then hybridized with primary antibodies and horseradish peroxidase (HRP)-conjugated secondary antibodies, followed by detection by chemiluminescence (Bio-Rad). Gels and blot images were analyzed using Image Lab Software 5.0. Antibodies to Snail1 (#3895, 1:1000), GAPDH (#5174, 1:2000), p38 (#9212, 1:1000), p-p38 (#9216, 1:1000), JNK (#9252, 1:1000), p-JNK (#9251, 1:1000), Tubulin (#3873, 1:1000), SP1 (#5931, 1:1000), HA-Tag (#5017, 1:1000), Cleaved-caspase 3 (#9654, 1:1000) and Flag-Tag (#8146, 1:1000) were purchased from Cell Signaling Technology (Danvers, MA, USA). USP36 antibody (14783-1-AP, 1:1000) was purchased from Proteintech (Chicago, IL, USA) and B23 antibody (MA5-12508, 1:1000) was purchased from ThermoFisher Scientific (Wilmington, DE, USA).

[0050] For endogenous co-immunoprecipitation (Co-IP), nucleoli were lysed in high-salt RIPA buffer (50 mM Tris pH 7.5, 500 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate and proteasome inhibitors). The cell lysate was centrifuged at 12,000 g for 30 min, and equal amounts of total protein were incubated with primary antibodies or normal IgG at 4 °C overnight, then 30 μl of protein A / G beads were added and incubated for another 2 h. For exogenous Co-IP, anti-HA magnetic beads (or anti-Flag magnetic beads) were added to equal amounts of protein solution and incubated overnight, then the magnetic beads were centrifuged (500 g, 30 s) and washed three times with washing buffer (20 mM Tris-HCl, 250 mM NaCl, 0.2 mM EGTA, 0.1% Nonidet P-40). They were heated at 100 °C for 10 min before western blot analysis. Anti-FLAG M2 affinity gel (A2220) was purchased from Sigma-Aldrich (St. Louis, USA) and Pierce Anti-HA magnetic beads (#88836) were purchased from Thermo Fisher Scientific (Waltham, MA, USA).

[0051] Immunofluorescence staining: Cells grown on coverslips were fixed with 4% paraformaldehyde, perforated with 0.1% Triton X-100, and blocked with 4% bovine serum albumin. Cells were then hybridized with appropriate primary antibodies (snail 1:50, sc-271977, Santa Cruz Biotechnology (CA, USA); USP36: 1:4000, 14783-1-AP, Proteintech; B23: 1:50, MA5-12508, ThermoFisher; HA-Tag: 1:1000, #5017, CST), Flag-Tag: 1:1000, #8146, CST), and then with secondary antibodies (goat anti-mouse Alexa Fluor 488, a-11029 or goat anti-rabbit Alexa Fluor 514, a-31558, ThermoFisher) and incubated with DAPI (#82961, CST) The cells were counterstained with Gold Antifade Reagent and photographed using a Leica TCS SP5II confocal laser scanning microscope. To determine the colocalization of Snail1 with nucleolar B23 or USP36, the free software Image J.Fiji combined with the Coloc 2 plug-in and the Pearson correlation coefficient were used to calculate the double fluorescence correlation coefficient, and the colocalization fluorescence was given by a scatter plot.

[0052] 2. Experimental Results

[0053] 1. HHT promotes the nucleolar aggregation of Snail1 protein

[0054] Snail1 is a key transcription factor localized in the nucleoplasm of the cell nucleus. It plays an important role in regulating biological processes such as epithelial-to-mesenchymal transition (EMT), cell survival, metabolic reprogramming, and tumor cell stemness. In order to explore the role of Snail1 in solid tumor cells' resistance to HHT, this experiment first used immunofluorescence staining to detect the effect of HHT on the subcellular localization of Snail1 protein. Figure 1 As shown in AB, HHT can significantly promote the co-localization of Snail1 protein and nucleolar marker B23 in breast cancer cells Hs578T, SUM159 and lung cancer cells A549. In addition, cell component separation experiments also showed that HHT can significantly promote the expression of Snail1 protein in the nucleolus of breast cancer cells HCC1806 ( Figure 1 C). The above results indicate that HHT can significantly promote the accumulation of Snail1 protein in the nucleolus.

[0055] 2. HHT promotes Snail1 protein nucleolar aggregation by increasing USP36 expression

[0056] Next, this experiment explored the molecular mechanism by which HHT promotes the nucleolar aggregation of Snail1 protein. Protein half-life analysis experiments revealed that HHT can significantly increase the stability of Snail1 protein ( Figure 2 A). Therefore, it is speculated that HHT may promote the aggregation of Snail1 protein in the nucleolus by increasing its stability. USP36 is a deubiquitinase specifically localized in the nucleolus. This experimental example found that HHT can significantly increase the expression of USP36 and Snail1 proteins ( Figure 2 B). Heterologous expression of wild-type USP36 (USP36-WT) significantly increased the expression of Snail1, but the USP36 deubiquitinase inactive mutant USP36-C131A had no significant effect on Snail1 protein expression ( Figure 2 C). In addition, knockdown of USP36 also significantly reduced Snail1 protein expression ( Figure 2 D). Complementation of USP36-WT completely restored the reduction of Snail1 protein mediated by USP36 knockdown, but complementation of USP36-C131A could not achieve this process ( Figure 2D). The results showed that USP36 positively regulated the expression of Sanil1 protein, and this process depended on the deubiquitinase activity of USP36. Furthermore, immunofluorescence staining was used to detect the effect of USP36 on the nucleolar localization of Snail1 protein. Figure 2 As shown in E, heterologous expression of USP36-WT can significantly promote the aggregation of Snail1 protein in the nucleolus, but USP36-C131A has no significant effect on the localization of Snail1 protein. Importantly, knocking down USP36 can significantly inhibit the nucleolar aggregation of Snail1 protein mediated by HHT. The above results indicate that HHT promotes the aggregation of Snail1 protein in the nucleolus by upregulating the expression of USP36.

[0057] 3. USP36 is a deubiquitinase for nucleolar Snail1

[0058] The above studies show that HHT promotes the nucleolar aggregation of Snail1 protein by increasing the expression of USP36. Further investigation is needed to determine whether USP36 is a deubiquitinase of the nucleolar Snail1 protein. Figure 3 As shown in A, USP36 and Snail1 form a stable protein complex in the nucleolus. Heterologous expression of USP36-WT can significantly increase the stability of Snail1 protein, but the deubiquitinase inactive mutant USP36-C131A has no significant effect on the stability of Snail1 protein ( Figure 3 B). Conversely, knockdown of USP36 significantly reduced the stability of Snal1 protein ( Figure 3 C) Next, the effect of USP36 on Snail1 protein ubiquitination was detected. Figure 3 As shown in D, heterologous expression of USP36-WT can significantly inhibit the ubiquitination of Snail1 protein, while USP36-C131A has no significant effect on the ubiquitination of Snail1 protein. Knockdown of USP36 significantly increased the ubiquitination of Snail1 protein ( Figure 3 E). Further, through point mutation analysis, it was found that lysine 146 (K146) and lysine 206 (K206) on the Snail1 protein are the deubiquitination sites of USP36. Figure 3 As shown in F, heterologous expression of USP36 significantly reduced the ubiquitination of wild-type Snail1 (Snail1-WT) protein, but had no significant effect on the ubiquitination of Snail1-K146R / K206R (Snail1-2KR). Protein half-life experimental analysis showed that heterologous expression of USP36 significantly increased the stability of Snail1-WT protein, but had no significant effect on the stability of Snail1-2KR protein ( Figure 3GH). In summary, the studies in this experimental example show that (1) USP36 is a deubiquitinase of the nucleolar Snail1 protein; (2) USP36 stabilizes the Snail1 protein by removing the ubiquitin chains on K146 and K206 of the Snail1 protein.

[0059] 4. Lysine 157 (K157) on Snail1 protein is a key site for the formation of Snail1-USP36 protein complex and Snail1 nucleolar localization

[0060] Bioinformatics prediction showed that lysine 157 (K157) on Snail1 protein may be the key amino acid residue for the formation of Snail1-USP36 protein complex ( Figure 4 A). Indeed, through point mutation and immunoprecipitation analysis, it was found that wild-type Snail1 protein can form a stable protein complex with USP36 in the nucleolus, but Snail1-K157R cannot form a protein complex with USP36 ( Figure 4 B). Further analysis of cell component separation and immunofluorescence staining revealed that overexpression of USP36 or HHT treatment could not promote the nucleolar aggregation of Snail1-K157R protein ( Figure 4 CF). The results showed that K157 on Snail1 protein is a key amino acid residue that regulates the formation of Snail1-USP36 protein complex and affects the nucleolar localization of Snail1.

[0061] 5. HHT upregulates USP36 expression by activating JNK

[0062] Next, we analyzed the molecular mechanism of HHT upregulating USP36 expression: Fluorescence quantitative PCR analysis showed that HHT could significantly increase the mRNA expression level of USP36 gene ( Figure 5 A). This suggests that HHT promotes USP36 transcription. Studies have shown that HHT can significantly activate the JNK signaling pathway, thereby regulating gene transcription. Therefore, we speculate that HHT may promote USP36 expression through the JNK signaling pathway. Figure 5 As shown in BC, HHT can significantly activate JNK, and the JNK specific inhibitor SP600125 can significantly inhibit the HHT-mediated increase in USP36 protein and mRNA expression levels. In addition, SP600125 also significantly inhibited the HHT-mediated Snail1 protein nucleolar aggregation ( Figure 5 D) These results indicate that HHT upregulates USP36 expression and Snail1 nucleolar aggregation by activating JNK.

[0063] In summary, this experimental study shows that HHT can significantly activate JNK and thus upregulate the expression of nucleolar deubiquitinase USP36; increased USP36 promotes Snail1 protein nucleolar aggregation and tumor cell survival by increasing the stability of nucleolar Snail1 protein. Therefore, activating the JNK-USP36-Snail1 signaling pathway is the key to solid tumors resisting HHT.

[0064] Experimental Example 2 Gene silencing of Snail1 or USP36 significantly promotes HHT-mediated tumor cell death in vitro and tumor growth inhibition in vivo

[0065] 1. Experimental Methods

[0066] 1. Lentiviral infection and RNA interference

[0067] Lentivirus-based shRNA targeting Snail1 (#1: 5′-CCACTCAGATGTCAAGAAGTA-3′ (SEQ ID NO.1); #2: 5′-CCAGGCTCGAAAGGCCTTCAA-3′ (SEQ ID NO.2)), USP36 (#1: 5′-GCGGTCAGTCAGGATGCTATT-3′ (SEQ ID NO.3); #2: 5′-ACAGAACATCCAACGTCTTAA-3′ (SEQ ID NO.4)) or green fluorescent protein (GFP, 5′-GAAGCAGCACGACTTCTTC-3′ (SEQ ID NO.5)) was constructed into the pLKO.1 plasmid. Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) was used to transfect pMD2G and psPAX2 packaging plasmids and pLKO.1 plasmid into HEK-293FT cells with a confluence of 70%, and the lentivirus was collected 60 hours after transfection. Under 10 μg / mL polystyrene conditions, the recombinant lentivirus was used to infect the target cells with a confluence of 60%, and finally a stable cell line with knockdown of the target gene was obtained.

[0068] 2. Cell apoptosis and cell viability assay

[0069] HCC1806 (human breast squamous cell carcinoma) cells were cultured in 6-well plates. When the cell confluence rate was about 70%, the cells were treated with 20 ng / mL alone or in combination with 20 μM JNK inhibitor SP600125 (S1460, Houston, USA) for 24 hours. The cells were then incubated with Annexin V-FITC and PI (Beyotime, C1052, China), and cell apoptosis was analyzed by flow cytometry (FACScan, BD Biosciences, USA). For cell viability, MTS detection was performed using the CellTiter 96 kit (Promega, USA).

[0070] 3. Animal Model

[0071] All animal experiments in this study were performed in accordance with Chinese national legislation and institutional ethical guidelines and approved by the Institutional Review Board of Sichuan University. Female BALB / c nude mice (BALB / cNj-Foxn1nu / Gpt) were purchased from GemPharmatech (Chengdu, China). 5 × 10 5 The HCC1806 cells shown were inoculated subcutaneously in the right neck of 6-week-old female BALB / c nude mice (n=5 / group). On the 3rd day after inoculation, the mice were intraperitoneally injected with HHT (1 mg / kg) every day. The tumor growth of the mice was dynamically observed, and the mice were killed on the 14th day after administration, and the tumors were removed and the volume and weight of the tumors were measured.

[0072] 2. Experimental Results

[0073] This experimental example explored the role of the JNK-USP36-Snail1 pathway in solid tumor cells' resistance to HHT. Figure 6 As shown in AB, knockdown of Snail1 significantly promoted HHT-mediated cleaved-caspase3 (CC3, a cell apoptosis marker) expression and cell apoptosis, a process that could be restored by wild-type Snail1 expressed in the nucleolus (Snail1-WT), but not by Snail1-K157R that lost its nucleolar localization. Importantly, knockdown of Snail1 also significantly promoted the inhibitory effect of HHT on tumor growth in vivo, a process that could also be restored by Snail1-WT, but not by Snail1-K157R ( Figure 6 CD). In addition, consistent with the knockdown of Snail1, the knockdown of USP36 also significantly promoted HHT-mediated CC3 expression and cell apoptosis, a process that was also restored by Snail1-WT but not by Snail1-K157R ( Figure 6EF). The above results indicate that (1) gene silencing of Snail1 or USP36 significantly promotes HHT-mediated tumor cell death in vitro and tumor growth inhibition in vivo; (2) nucleolar Snail1 is the key to tumor cell resistance to HHT.

[0074] Experimental Example 3: Combination of JNK inhibitor SP600125 and HHT significantly inhibited tumor cell survival in vitro and tumor growth in vivo

[0075] 1. Experimental Methods

[0076] 1. Cell apoptosis and cell viability assay

[0077] Hs 578T (human breast cancer), HCC1806 (human breast squamous carcinoma) and SUM159 (human breast cancer) cells were cultured in 6-well plates. When the cell confluence was about 70%, the cells were treated with 20 ng / mL HHT alone or in combination with 20 μM JNK inhibitor SP600125 (S1460, Houston, USA) for 24 hours. The cells were then incubated with Annexin V-FITC and PI (Beyotime, C1052, China), and cell apoptosis was analyzed by flow cytometry (FACScan, BD Biosciences, USA). For cell viability, MTS detection was performed using the CellTiter 96 kit (Promega, USA).

[0078] 2. Animal Model

[0079] All animal experiments in this study were performed in accordance with Chinese national legislation and institutional ethical guidelines and approved by the Institutional Review Board of Sichuan University. Female BALB / c nude mice (BALB / cNj-Foxn1nu / Gpt) were purchased from GemPharmatech (Chengdu, China). 5 × 10 5 HCC1806 cells were inoculated subcutaneously in the right neck of 6-week-old female BALB / c nude mice (n=5 / group). On the 3rd day after inoculation, mice were intraperitoneally injected with DMSO (5% V / V) or SP600125 (15 mg / kg) and / or HHT (1 mg / kg) every day. The size of the tumor in mice was monitored every day. On the 17th day after intraperitoneal administration, the mice were killed, the tumors were removed and the weight of the tumors was measured.

[0080] 2. Experimental Results

[0081] This experiment explored the role of JNK in solid tumor cells' resistance to HHT. Figure 7As shown in AB, compared with the use of HHT or JNK inhibitor SP600125 alone, the combination of HHT and SP600125 significantly promoted the expression of cleaved-caspase3 (CC3) and cell apoptosis. Importantly, the combination of HHT and SP600125 significantly promoted the expression of CC3 in tumor tissues in vivo and significantly inhibited tumor growth in vivo ( Figure 7 CD). The results suggest that the combination of JNK inhibitor SP600125 and HHT is a potential new strategy for tumor treatment.

[0082] Experimental Example 4: Combining JNK inhibitor SP600125 and ribosome inhibitor anisomycin or blasticidin significantly inhibited the survival of tumor cells in vitro

[0083] 1. Experimental Methods

[0084] 1. Cell apoptosis assay

[0085] HCC1806 (human breast squamous cell carcinoma) cells were cultured in 6-well plates. When the cell confluence was about 70%, the cells were treated with 20 ng / mL HHT, 50 ng / mL anisomycin, 200 ng / mL puromycin, 1 μg / mL G418, 2 μg / mL blasticidin alone or in combination with 20 μM JNK inhibitor SP600125 (S1460, Houston, USA) for 24 h. The cells were then incubated with Annexin V-FITC and PI (Beyotime, C1052, China), and cell apoptosis was analyzed by flow cytometry (FACScan, BD Biosciences, USA).

[0086] 2. Experimental Results

[0087] This experiment investigated the role of JNK in solid tumor cells' resistance to the ribosomal inhibitors anisomycin or blasticidin. Figure 8 As shown in AC, consistent with HHT, ribosomal inhibitors anisomycin (Aniso), puromycin (Puro), G418, or blasticidin (Blasti) can significantly promote the nucleolar localization of Snail1 protein. Importantly, JNK inhibitor SP600125 and anisomycin or blasticidin significantly promoted the expression of CC3 in cells and significantly promoted cell apoptosis ( Figure 8 DE).

[0088] The results of this experiment show that the mechanism by which solid tumors resist multiple ribosome inhibitors is the same, that is, through the JNK-USP36-Snail signaling pathway. Therefore, the combination of JNK-USP36-Snail pathway inhibitors and ribosome inhibitors is a potential new strategy for tumor treatment.

[0089] From the above experimental examples, we can see that targeted inhibition of the JNK-USP36-Snail signaling pathway will enhance the sensitivity of solid tumor cells to ribosome inhibitors; the combination of ribosome inhibitors and JNK-USP36-Snail pathway inhibitors is a new strategy for the treatment of solid tumors. The present invention provides a new option for the clinical treatment of solid tumors and has a good application prospect.

Claims

1. Use of a ribosome inhibitor combined with a JNK-USP36-Snail pathway inhibitor in the preparation of a drug for treating breast cancer, characterized in that: The ribosome inhibitor is selected from homoharringtonine; The JNK-USP36-Snail pathway inhibitor is selected from at least one of shRNA-Snail1, shRNA-USP36, and SP600125; The nucleotide sequence of the shRNA-Snail1 is selected from at least one of SEQ ID NO.1- SEQ ID NO.2; The nucleotide sequence of the shRNA-USP36 is selected from at least one of SEQ ID NO.3-SEQ ID NO.

4.

2. Use of a ribosome inhibitor combined with a JNK-USP36-Snail pathway inhibitor in the preparation of a drug for treating breast cancer, characterized in that: The ribosome inhibitor is selected from at least one of anisomycin and blasticidin; The JNK-USP36-Snail pathway inhibitor is selected from SP600125.